Biography

Dr. Suresh S. Ramalingam is the executive director of the Winship Cancer Institute of Emory University. He also serves as professor of hematology and medical oncology and the Roberto C. Goizueta Chair for Cancer Research at the Emory University School of Medicine.

Dr. Ramalingam’s research is focused on the development of novel treatment approaches for patients with lung cancer. Specifically, his group has developed novel treatment options for lung cancer patients harboring an EGFR mutation, resulting in FDA approval of third generation inhibitors for metastatic and locally-advanced non-small cell lung cancer. He leads clinical and translational investigations of novel immunotherapy approaches for the treatment of lung cancer and serves as the principal investigator for the Emory University Lung Cancer SPORE award from the National Cancer Institute (NCI).

Dr. Ramalingam has published more than 400 peer-reviewed publications, with over 36,000 citations and an H-index of 80. His research has been published in leading journals including the The New England Journal of Medicine, The Lancet, Science, Nature, The Proceedings of the National Academy of Sciences, The Journal of Clinical Investigation, and the Journal of Clinical Oncology. Additionally, Dr. Ramalingam is the editor-in-chief of Cancer, a journal of the American Cancer Society.

The recipient of numerous awards, Dr. Ramalingam has been honored with the James R. Eckman Award for Excellence at Emory University, Paul Bunn Jr Award for Scientific Merit (IASLC), the Georgia Cancer Coalition’s Distinguished Cancer Scholar Award, the ECOG Young Investigator Award (2013), the NCI Clinical Investigators Team Leadership Award (2010-2012), and the ASCO Career Development Award (2006–2009).

Dr. Ramalingam is deputy chair for Therapeutics Programs at ECOG-ACRIN and a former chair of the ECOG-ACRIN Thoracic Malignancies Committee. He served as a member of the boards of directors for the International Association for the Study of Lung Cancer (2017-2021) and Emory Healthcare and as a member of the NCI Thoracic Malignancies Steering Committee (2012-2021). He is a member of the NCI Clinical Trials and Translational Research Advisory Committee. He also serves on the board of the Georgia Center for Oncology Research and Education.